Anti-platelets in diabetes management.
This study aimed to determine the prevalence of anti-platelet use, and the extent to which contraindications to anti-platelet therapy prevent its use, in 726 diabetic patients attending a private clinic. Among those who reported a history of cardiovascular disease (CVD), 87.1% were on anti-platelet therapy. Of those without prior CVD but with at least one CVD risk factor, 59.8% were not on anti-platelet therapy, but only 7.1% of these had a contraindication to anti-platelet therapy. This study showed that high usage of anti-platelet therapy in diabetic patients with prior CVD is achievable, and that contraindications did not explain low use in those without prior CVD.
Grantham
N M
NM
Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. Narelle.grantham@bakeridi.edu.au
Magliano
D J
DJ
Tai
G
G
Cohen
N
N
Shaw
J E
JE
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy* / Q000628:therapy; D019468:Disease Management; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010976:Platelet Count / Q000379:methods; D017713:Platelet Transfusion; D055815:Young Adult
D010975:Platelet Aggregation Inhibitors